In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diagnostics In 2014: More Of The Same

Executive Summary

In many ways, the year in diagnostics can be characterized as “more of the same.” The biggest newsmaker was FDA’s finally taking steps toward establishing an oversight framework for the regulation of laboratory-developed tests.

Advertisement

Related Content

Biopharma In 2014: Early Access Gains Offset Taxation, Pricing Woes
Medtech In 2014: M&A, IPOs Bounce Back As Industry Glimpses Future Business Models
CMS Proposes To Cover CT Lung Cancer Screening, With Lengthy Criteria
Advanced Diagnostics: Innovation, Reimbursement, And Coverage Challenges
Parallel Review Progress: FDA Approves, CMS Assesses Cologuard Cancer Test
FDA Plan To Regulate LDTs Includes Long Phase-In, Unmet-Need Exceptions
When Illumina Buys Roche: The Dawning Of The Era Of Diagnostics Dominance
Option Deal Structure Works For Myriad As It Moves To Buy Crescendo
2013: The Year In Diagnostics
Illumina’s Unique Leverage In NIPT

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004291

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel